Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epirubicin micelle formulation - NanoCarrier/Kowa

Next Previous
Drug Profile

Epirubicin micelle formulation - NanoCarrier/Kowa

Alternative Names: K-912; NC 6003; NC-6300

Latest Information Update: 04 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoCarrier
  • Developer Kowa; NanoCarrier
  • Class Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 04 Jan 2022 Epirubicin micelle formulation - NanoCarrier/Kowa receives Fast Track designation for Soft tissue sarcoma [IV,Infusion] (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NanoCarrier pipeline, January 2022)
  • 28 Sep 2021 Phase I/II trial in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) is still ongoing in USA (IV) (NanoCarrier's pipeline, September 2021)
  • 28 Sep 2021 Phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) is still ongoing in USA (IV) (NanoCarrier's pipeline, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top